Andra AP fonden Buys 41,670 Shares of Insmed, Inc. $INSM

Andra AP fonden boosted its stake in Insmed, Inc. (NASDAQ:INSM) by 114.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 77,970 shares of the biopharmaceutical company’s stock after buying an additional 41,670 shares during the quarter. Andra AP fonden’s holdings in Insmed were worth $12,750,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of INSM. EverSource Wealth Advisors LLC boosted its holdings in Insmed by 65.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 664 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 263 shares during the last quarter. First Trust Advisors LP raised its holdings in shares of Insmed by 80.8% in the second quarter. First Trust Advisors LP now owns 47,392 shares of the biopharmaceutical company’s stock valued at $4,770,000 after purchasing an additional 21,176 shares during the last quarter. Baird Financial Group Inc. bought a new position in shares of Insmed during the second quarter valued at about $2,589,000. Amundi boosted its holdings in Insmed by 21,194.4% during the second quarter. Amundi now owns 11,499 shares of the biopharmaceutical company’s stock worth $1,130,000 after purchasing an additional 11,445 shares during the last quarter. Finally, Natixis purchased a new position in Insmed during the second quarter worth about $1,072,000.

Insider Transactions at Insmed

In other news, CEO William Lewis sold 21,398 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $103.32, for a total transaction of $2,210,841.36. Following the transaction, the chief executive officer owned 258,917 shares of the company’s stock, valued at $26,751,304.44. This represents a 7.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 2,370 shares of Insmed stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $242,379.90. Following the completion of the sale, the chief operating officer directly owned 98,603 shares of the company’s stock, valued at approximately $10,084,128.81. This trade represents a 2.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 54,590 shares of company stock worth $5,793,738 over the last quarter. 2.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research note on Wednesday, June 10th. Stifel Nicolaus boosted their target price on Insmed from $205.00 to $208.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Barclays upped their target price on Insmed from $231.00 to $237.00 and gave the company an “overweight” rating in a report on Wednesday, April 1st. Raymond James Financial began coverage on Insmed in a research report on Friday, April 10th. They set an “outperform” rating and a $200.00 price target for the company. Finally, Bank of America lifted their price target on Insmed from $211.00 to $213.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Insmed has an average rating of “Moderate Buy” and an average price target of $209.13.

Insmed Trading Up 1.5%

NASDAQ:INSM opened at $108.62 on Wednesday. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. The stock has a market capitalization of $23.54 billion, a PE ratio of -18.89 and a beta of 0.78. The firm’s 50 day moving average is $105.64 and its 200 day moving average is $134.69. Insmed, Inc. has a 12 month low of $90.39 and a 12 month high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The business had revenue of $305.96 million during the quarter, compared to analyst estimates of $300.81 million. During the same period in the prior year, the company earned ($1.42) earnings per share. Insmed’s revenue was up 229.7% compared to the same quarter last year. Sell-side analysts expect that Insmed, Inc. will post -2.43 earnings per share for the current year.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.